Does Group Health Cooperative (GHC) Cover Eliquis?

Understanding GHC's Transition to Kaiser Permanente Washington

Group Health Cooperative completed its merger with Kaiser Permanente in February 2017, and prescription drug benefits now fall under the Kaiser Permanente Washington formulary system. If your insurance card still references "Group Health Cooperative," your pharmacy benefits are administered through Kaiser Permanente's integrated model. This distinction matters because formulary searches should be conducted through Kaiser Permanente Washington's drug lookup tool, not legacy GHC databases.

Kaiser Permanente Washington operates an integrated pharmacy model where medications are dispensed through Kaiser Permanente pharmacies or contracted retail networks. Eliquis has maintained formulary placement throughout this transition. The American College of Cardiology and the American Heart Association jointly recommend direct oral anticoagulants (DOACs) including apixaban as first-line therapy over warfarin for most patients with non-valvular atrial fibrillation, which supports its formulary inclusion across most major insurers [1]. Kaiser Permanente's national formulary committee evaluates DOACs based on clinical evidence, safety profiles, and negotiated pricing, and Eliquis has consistently met inclusion criteria since its FDA approval in 2012 [2].

How Eliquis Is Classified on the Kaiser Permanente Washington Formulary

Eliquis sits on Tier 2 (preferred brand) or Tier 3 (non-preferred brand) depending on the specific plan purchased through Kaiser Permanente Washington. The tier placement directly determines your out-of-pocket cost per fill.

For most commercial HMO and POS plans, Eliquis is classified as a preferred brand. Members on these plans typically pay between $35 and $60 for a 30-day supply after meeting their annual deductible. High-deductible health plans (HDHPs) paired with a health savings account require members to pay the full negotiated price until the deductible is met, which can mean paying $500 or more per month during the deductible phase. Medicare Advantage plans offered through Kaiser Permanente Washington place Eliquis on their Part D formulary, often at Tier 3, with copays ranging from $42 to $95 depending on the coverage phase [3].

The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared to warfarin (HR 0.79; 95% CI, 0.66 to 0.95; P<0.001 for noninferiority; P=0.01 for superiority) while also reducing major bleeding by 31% and all-cause mortality by 11% [4]. This dual benefit of superior efficacy with lower bleeding risk is a primary reason insurers maintain Eliquis on preferred formulary tiers despite its higher acquisition cost compared to warfarin.

Prior Authorization and Step Therapy Requirements

Most Kaiser Permanente Washington plans do not require prior authorization for Eliquis when prescribed for FDA-approved indications: reduction of stroke risk in non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prophylaxis of DVT following hip or knee replacement surgery [2].

Prior authorization is more likely to be triggered in specific situations. Off-label uses, doses outside the standard 5 mg or 2.5 mg twice-daily regimens, or requests exceeding quantity limits may prompt a pharmacy review. The FDA-approved dose reduction criteria specify apixaban 2.5 mg twice daily for patients meeting at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater [2]. Prescriptions falling outside these parameters could require clinical justification.

Step therapy (requiring a trial of a cheaper alternative first) is uncommon for atrial fibrillation indications at Kaiser Permanente Washington. The 2019 AHA/ACC/HRS Focused Update gives DOACs a Class I recommendation over warfarin for eligible patients with atrial fibrillation, making it difficult for insurers to mandate warfarin as a first-line step [5]. Dr. Craig January, lead author of the 2014 AHA/ACC/HRS Atrial Fibrillation Guideline, stated: "DOACs are preferred over warfarin in most patients with AFib who are eligible for oral anticoagulation, based on their overall profile of efficacy, safety, and convenience" [5].

For DVT/PE prophylaxis after orthopedic surgery, some plans may prefer rivaroxaban (Xarelto) due to its once-daily dosing and potentially lower negotiated cost, but outright denial of Eliquis for this indication is rare.

What Eliquis Costs Under Different GHC/Kaiser Permanente Washington Plans

Out-of-pocket costs vary significantly by plan type. Here is a breakdown based on common Kaiser Permanente Washington plan structures.

Commercial HMO plans typically charge a flat copay of $35 to $60 per 30-day supply for preferred brand medications. The copay applies after any applicable deductible. Some plans with integrated pharmacy benefits waive the deductible for prescription drugs entirely, meaning the copay applies from the first fill.

Commercial PPO/POS plans may use coinsurance rather than flat copays. Members on these plans might pay 20% to 30% of the negotiated drug cost, which translates to roughly $90 to $150 per month for Eliquis at its approximate wholesale acquisition cost of $500 to $550 for a 30-day supply [6].

Medicare Advantage (Part D) plans follow the standard Medicare Part D coverage phases. During the initial coverage phase, copays for Tier 3 brand drugs range from $42 to $95. Once a member enters the coverage gap (the "donut hole"), they pay 25% of the negotiated price for brand-name drugs under the Inflation Reduction Act provisions that took full effect in 2025 [3]. The $2,000 annual out-of-pocket cap on Part D spending, implemented in 2025, means total annual Eliquis costs for Medicare beneficiaries are now capped regardless of coverage phase.

Medicaid managed care plans administered through Kaiser Permanente Washington's Apple Health contracts generally cover Eliquis with minimal or zero copay, though prior authorization requirements may be stricter than commercial plans.

According to a 2023 analysis published in the Journal of the American Heart Association, the median annual out-of-pocket cost for DOAC users with commercial insurance was $684, compared to $132 for warfarin users (P<0.001) [7]. The cost difference is real but must be weighed against warfarin's need for regular INR monitoring, dietary restrictions, and higher rates of intracranial hemorrhage.

How to Reduce Your Eliquis Costs Through GHC/Kaiser Permanente Washington

Several cost-reduction strategies exist for Kaiser Permanente Washington members taking Eliquis.

Bristol-Myers Squibb's Eliquis 360 Support Program offers a copay card that reduces out-of-pocket costs to as low as $10 per month for commercially insured patients. The program covers up to $6,400 per year in copay assistance. Medicare and Medicaid beneficiaries are not eligible for the manufacturer copay card due to federal anti-kickback statutes [6].

90-day mail-order fills through Kaiser Permanente's mail-order pharmacy often reduce the per-unit cost. Many plans charge 2.0 to 2.5 times the 30-day copay for a 90-day supply rather than three full copays, saving members 17% to 33% on each fill cycle.

Formulary exceptions can be requested if Eliquis is placed on a non-preferred tier for your specific plan. Your prescribing physician submits a formulary exception form documenting medical necessity. Reasons that support an exception include documented bleeding events on alternative anticoagulants, inability to comply with rivaroxaban's food requirement (must be taken with a meal for the 15 mg and 20 mg doses), or renal impairment that contraindicates other DOACs [8].

Patient assistance programs are available through Bristol-Myers Squibb and Pfizer for uninsured or underinsured patients. These programs can provide Eliquis at no cost to qualifying individuals with household incomes below 300% of the federal poverty level.

Comparing Eliquis to Other Covered Anticoagulants on the GHC Formulary

Kaiser Permanente Washington's formulary includes multiple anticoagulant options, and understanding the alternatives helps contextualize Eliquis coverage decisions.

Warfarin (generic) is Tier 1 on virtually every formulary, with copays of $0 to $15 per month. It requires regular INR monitoring (typically every 2 to 4 weeks for stable patients) and has significant drug-food interactions. The RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials collectively enrolled over 70,000 patients and consistently showed DOACs to be at least non-inferior to warfarin for stroke prevention, with lower rates of intracranial hemorrhage across all four agents [4][9][10].

Rivaroxaban (Xarelto) is typically on the same formulary tier as Eliquis. Once-daily dosing is an advantage for adherence, but the ROCKET AF trial showed rivaroxaban was non-inferior (not superior) to warfarin for stroke prevention, with similar major bleeding rates [10]. A large retrospective analysis published in BMJ (N=581,451) found apixaban was associated with lower rates of major bleeding compared to rivaroxaban (HR 0.59; 95% CI 0.55 to 0.62) with similar effectiveness for stroke prevention [11].

Dabigatran (Pradaxa) may sit on a lower formulary tier at some Kaiser Permanente regions due to its earlier generic entry (generic dabigatran received FDA approval in 2024). Its main disadvantage is twice-daily dosing combined with higher rates of gastrointestinal bleeding compared to warfarin in the RE-LY trial [9]. The availability of idarucizumab (Praxbind) as a specific reversal agent is a clinical advantage.

Dr. Renato Lopes, a principal investigator of the ARISTOTLE trial, noted: "Among the DOACs, apixaban has the most favorable balance of efficacy and safety, particularly regarding major bleeding and intracranial hemorrhage risk" [4].

When Coverage May Be Denied and How to Appeal

Coverage denials for Eliquis through Kaiser Permanente Washington are uncommon for standard indications but do occur. The most frequent denial reasons include formulary exclusion on a specific narrow plan, quantity limit exceptions not meeting clinical criteria, and off-label use without supporting evidence.

The appeal process follows Washington State insurance regulations. Members have 180 days from the date of denial to file an internal appeal. Kaiser Permanente Washington must respond to standard appeals within 30 calendar days and urgent (expedited) appeals within 72 hours. If the internal appeal is denied, members can request an external review through the Washington State Office of the Insurance Commissioner.

Successful appeals typically include a letter of medical necessity from the prescribing physician, documentation of the specific FDA-approved indication, any relevant lab work (renal function, liver function), and records of prior anticoagulant trials if step therapy was cited as the denial reason. The AHA/ACC/HRS guidelines serve as strong supporting evidence for DOACs as first-line therapy [5].

For Medicare Advantage members, Part D coverage determination requests follow CMS guidelines. The prescribing physician can request an expedited coverage determination, which requires a decision within 24 hours for urgent situations such as a patient being discharged from the hospital after a DVT or PE event.

Checking Your Specific Coverage Before Filling a Prescription

Three steps confirm your exact Eliquis coverage under Kaiser Permanente Washington. First, log into kp.org/wa and use the "Estimate Drug Costs" tool with your member ID. Second, call the pharmacy benefits number on the back of your member ID card for real-time formulary verification. Third, ask your Kaiser Permanente pharmacy at the point of sale. They can run a test claim to determine your exact copay before you commit to the fill.

Benefit structures reset annually, and formulary changes take effect each plan year (January 1 for most commercial plans). A medication that was Tier 2 this year could shift to Tier 3 during the next open enrollment cycle. The Centers for Medicare and Medicaid Services require Part D plans to provide at least 60 days' notice before removing a drug from the formulary or moving it to a less favorable tier mid-year [3].